STEP THERAPY POLICY

POLICY: Gabapentin Step Therapy Policy

- Gralise® (gabapentin extended release tablets Almatica, generic)
- Horizant® (gabapentin enacarbil extended-release tablets Arbor)
- Neurontin[®] (gabapentin capsules, tablets, and solution Pfizer, generic)

REVIEW DATE: 02/07/2024

OVERVIEW

Gabapentin, gabapentin ER (Gralise, generic), and Horizant are indicated for the following uses:¹⁻³

- Management of **postherpetic neuralgia** in adults.
- Gabapentin is also approved as adjunctive therapy in the treatment of **partial onset seizures**, with and without secondary generalization, in adults and children ≥ 3 years of age with epilepsy.
- Horizant is also indicated for moderate-to-severe **restless leg syndrome** (RLS) in adults.

Gabapentin ER (Gralise, generic) and gabapentin (Neurontin, generic) are analogs of the neurotransmitter gamma-aminobutyric acid (GABA).^{1,2} Horizant is a prodrug of gabapentin.³ These drugs exert their pharmacologic action by binding to the alpha-2-delta subunit of voltage-gated calcium channels.^{1,3} The binding of this subunit reduces the release of several neurotransmitters including glutamate, noradrenaline, and substance P. Gabapentin is available as capsules, tablets, and oral solution; gabapentin ER and Horizant are available as extended-release (ER) tablets. Product labeling for gabapentin ER and Horizant note that they are not to be used interchangeably with other gabapentin products due to different pharmacokinetic profiles that affect frequency of administration or different plasma concentrations relative to other gabapentin products. Gabapentin ER and Horizant are dosed once daily and should be taken with evening meals, whereas gabapentin is dosed three times a day and can be taken without regard to food.

POLICY STATEMENT

This program has been developed to encourage the use of a Step 1 Product prior to the use of a Step 2 Product. If the Step Therapy rule is not met for a Step 2 Product at the point of service, coverage will be determined by the Step Therapy criteria below. All approvals are provided for 1 year in duration.

<u>Automation</u>: A patient with a of one Step 1 Product within the 130-day look-back period is excluded from Step Therapy.

Step 1: generic gabapentin capsules, tablets, and oral solution

Step 2: Gralise (brand and generic), Horizant, Neurontin

CRITERIA

- 1. If the patient has tried one Step 1 Product (brand [Neurontin] or generic), approve a Step 2 Product.
- 2. No other exceptions are recommended.

REFERENCES

Gabapentin Step Therapy Policy Page 2

- Neurontin® capsules, tablets, oral solution [prescribing information]. New York, NY: Pfizer; July 2022.
- Gralise® tablets [prescribing information]. Morristown, NJ: Almatica; April 2023. Horizant® extended-release tablets [prescribing information]. Atlanta, GA: Arbor; August 2022.